While the term “biotechnology” was coined in 1919, “techbio” dates back roughly a century after that. Around 2019, the VC firm Artis Ventures set up a venture capital fund named Artis techbio with the aim of uniting software, computational biology, and drug development into a cohesive framework. The ambition behind this idea has sometimes surpassed…
3 ‘radical’ premises to reshape pharma R&D with AI—starting with holding off on AI
A good number of organizations rushing to deploy AI in pharmaceutical and genomics research have their priorities backward. They need not only a solid data infrastructure but also true data savviness before forging ahead with deep learning or large language models, argues Stavros Papadopoulos, CEO and founder of TileDB, the developer of data platform for…